Efficacy of epirubicin plus docetaxel or paclitaxel in the treatment of breast cancer

Purpose: To determine the clinical efficacy of epirubicin plus docetaxel or paclitaxel in management breast cancer. 
 Methods: This study was a randomized controlled trial that recruited 78 patients with cancer treated The First People’s Hospital Anqing between December 2018 and March 2021. participants were to receive either (control group) (study group), 39 cases each group. Clinical outcomes, adverse events, quality life, prognosis two groups compared. Results: Epirubicin produced greater than (p < 0.05). combination also exhibited higher safety profile versus docetaxel, as evidenced by lower incidences nausea vomiting, intestinal discomfort, muscle pain, dyspnea reactions resulted improvement life 0.05) well provided more benefits terms survival recurrence control Conclusion: Epirubicin/paclitaxel alleviates symptoms, reduces enhances patient prognosis, lowers risk postoperative recurrence, provides superior when compared epirubicin/docetaxel patients. Nonetheless, large-scale better-randomized trials are required validate findings this study.